| Autor: |
Sullivan KM; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland., Dores GM; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland., Nayernama A; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland., Prowell TM; Office of Oncologic Diseases, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland.; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Pradhan SM; Office of Oncologic Diseases, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland., Osgood C; Office of Oncologic Diseases, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland., Jones SC; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland. |
